Cargando…
AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma
BACKGROUND: Lenvatinib is an orally administered drug that works as a multi-targeted tyrosine kinase inhibitor. It has been approved as a first-line drug after sorafenib in hepatocellular carcinoma (HCC). However, little is currently known about its treatment, targets, and possible resistance in HCC...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331763/ https://www.ncbi.nlm.nih.gov/pubmed/37435231 http://dx.doi.org/10.21037/jgo-23-277 |